You just read:

Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint

News provided by

Array BioPharma

Sep 26, 2016, 07:00 ET